Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access
1
Issued Date
2025-12-01
Resource Type
eISSN
20452322
Scopus ID
2-s2.0-105009538592
Journal Title
Scientific Reports
Volume
15
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Scientific Reports Vol.15 No.1 (2025)
Suggested Citation
Suttantapidok S., Kungwankiattichai S., Owattanapanich W. Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access. Scientific Reports Vol.15 No.1 (2025). doi:10.1038/s41598-025-07187-z Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/111134
Title
Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Classical Hodgkin lymphoma (cHL) is a highly-curable, aggressive form of lymphoma with disparities between international guidelines and treatment in resource-limited countries. We aimed to report outcomes in a multi-centered retrospective cohort of all cHL patients ≥ 18 years old exclusively treated with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) without positron emission tomograph (PET)-adapted treatment between 2013 and 2022 in Thailand. First-line core treatment goals (FL-CTGs) for a resource-limited middle-income country were also investigated. One hundred ninety-two patients were included (median age 28.0 years, range 15, 79). The patients had an objective response rate of 90%. The 3-year overall survival (OS) was 94.6% (95%CI 89.8%, 97.2%), and the 3-year progression-free survival (PFS) was 62.2% (95%CI 54.2%, 69.3%). Both 3-year OS and PFS rates were higher in patients achieving FL-CTGs compared with those not achieving them in the early stage (Ann Arbor stages I and II) and advanced stage (Ann Arbor stages III and IV) groups. Advanced-stage patients not achieving FL-CTGs had a significantly higher risk of progression, relapse, or all-cause mortality (aHR 3.77, 95%CI 1.74, 8.17; p < 0.001). In conclusion, cHL patients treated exclusively with ABVD without PET-adapted treatment had good survival outcomes and achieving FL-CTGs is essential for good survival outcomes.